Dietary l-lysine supplementation altered the content of pancreatic polypeptide, enzymes involved in glutamine metabolism, and β-actin in rats
- 273 Downloads
This study investigated the effects of Lys supplementation on serum pancreatic polypeptide (PP), glutamine (Gln) levels and the expression of PP, Gln synthetase (GlnS), glutaminase (Gls) and β-actin in different tissues such as pancreas, skeletal muscle, liver and kidney in rats. Male Sprague–Dawley rats were fed diets containing 7% casein supplemented with either 0% (Control), 1%, 1.5%, 3% Lys or 3% Lys with 1.5% Arg for a week. All rats were necropsied for collection of blood and tissues. Expression of PP, GlnS, Gls, and β-actin in tissues were determined using Western blotting. The results showed that the rats fed 3% supplemental Lys had significantly lower body weight gain (BWG) and food intake than the ≤ 1.5% Lys groups (P < 0.05). Supplementation with ≥ 1% Lys increased serum PP level (P < 0.05), but had no significant effect on pancreatic PP abundance (P > 0.05). GlnS expression was significantly lowered in skeletal muscle by ≥ 1.5% supplemental Lys compared to the Control (P < 0.05). The expression of Gls in the kidney was increased by the addition of 1.5% Arg to 3% Lys diet (P < 0.05). Liver β-actin significantly increased with both Lys and Arg supplementation and muscle β-actin significantly decreased (P < 0.05) with ≥ 1.5% supplemental Lys. Kidney β-actin significantly increased with Arg supplementation vs 3% Lys alone (P < 0.05). These results showed that dietary supplementation with ≥ 1.5% Lys significantly suppressed GlnS expression in the skeletal muscle, which may contribute to the decreased serum Gln levels, and that increased serum PP by Lys may be due to suppressed catabolism rather than increased synthesis of PP. Lys-induced PP may play a role in reducing food intake and BWG.
Keywordsl-Lysine supplementation l-Arginine Pancreatic polypeptide Glutamine β-Actin Rats
Body weight gain
This research was funded by Health Canada.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving animals
The animal experimental protocol (ACC#2016-006) was approved by the Health Canada-Ottawa Animal Care Committee, and all animal handling and care followed the guidelines of the Canadian Council for Animal Care.
All authors in this paper have read the final manuscript and approved for publication.
- Fouque D, Laville M, Boissel JP (2006) Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev 2:CD001892Google Scholar
- Pavlyk I, Rzhepetskyy Y, Jagielski AK, Drozak J, Wasik A, Pereverzieva G, Olchowik M, Kunz-Schugart LA, Stasyk O, Redowicz MJ (2015) Arginine deprivation affects glioblastoma cell adhesion, invasiveness and actin cytoskeleton organization by impairment of beta-actin arginylation. Amino Acids 47:199–212CrossRefGoogle Scholar
- Xiao CW, Wood CM, Swist E, Nagasaka R, Sarafin K, Gagnon C, Fernandez L, Faucher S, Wu HX, Kenney L, Ratnayake WM (2016) Cardio-metabolic disease risks and their associations with circulating 25-hydroxyvitamin D and omega-3 levels in South Asian and white Canadians. PLoS One 11:e0147648CrossRefGoogle Scholar